BioRevolution to Participate in BIO Partnering Conference and Global Biotech Events During the 44th Annual JP Morgan Healthcare Conference
Redwood City, CA, Jan. 5, 2026 – BioRevolution, a next-generation biotech company dedicated to building, restoring, and preserving muscle mass and strength for longevity, today announced that it will be attending the BIO Partnering Conference and other key industry events in San Francisco during the 44th Annual JP Morgan Healthcare Conference (January 12-15, 2026), including Global IR Pitching on January 13, 2026.
The team will showcase BREV‑100, a first‑in‑class oral small molecule targeting the glycogen degradation pathway with initial focus on Pompe disease and broader potential across multiple muscle wasting conditions.
“We look forward to connecting with investors, partners, and collaborators to accelerate the development of BREV-100 and enhance longevity for patients living with rare and chronic diseases worldwide,” said Thomas Butler, Chief Executive Officer.
About BioRevolution
BioRevolution is a biopharmaceutical company dedicated to building, restoring, and preserving muscle mass and strength for Longevity. Our approach harnesses the body’s natural, evolutionary mechanism of building functional muscle with broad applicability across multiple muscle wasting diseases, including Glycogen Storage Disorders, Muscular Dystrophies, Obesity, and Sarcopenia.
The company’s lead program, BREV-100, is a first-in-class, oral small molecule that targets the glycogen degradation pathway to activate the body’s central mechanism of building functional skeletal muscle starting with Pompe disease, where excess glycogen drives progressive muscle impairment.
BioRevolution is led by a seasoned team that has advanced multiple innovative therapies into the clinic and is united by a mission to transform muscle biology and extend healthy human lifespan for millions of patients living with rare and chronic diseases.
Company Contact:
info@biorevolutiontx.com
